BG-12, Biogen Idec's Novel Oral Compound Shown To Significantly Reduced Brain Lesions In Patients With Multiple Sclerosis Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when compared to treatment with placebo (p
Source: www.medicalnewstoday.comPharmaceutical Care Management Association: New Analysis Highlights The Need For Rapid Physician Adoption Of E-Prescribing Pharmaceutical Care Management Association (PCMA) released the following statement on a new analysis of federal data by the Institute for Safe Medications that found the Food and Drug Administration (FDA) has received a record number of reports of serious drug reactions, including more than 4,800 deaths: "This new analysis reinforces the Institute of
Medicine's (IoM) recommendation that all physicians begin prescribing electronically by 2010 to help prevent the 1.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 PM
